Whether “ total suppression” of the conversion of t to dht throughout the body by a single drug, or a combination of agents, will improve the treatment of prostatism remains to be determined, for instance, famotidine pregnancy!

Hospitalization may be required if the patient's breathing is particularly difficult, or if close observation by medical personnel, intravenous medications, supplemental oxygen are required.

We believe that the impressive and growing body of data from patients receiving Provenge supports the utility of this product candidate as an important new approach to treating prostate cancer, and validates our leading cancer vaccine platform. With the worldwide market for prostate cancer therapies approaching $3 billion, we believe that Provenge will benefit patients while also providing value to our shareholders. The success of Provenge is an important driver for our future growth, but Dendreon also has a number of other programs with great medical and commercial potential in preclinical and clinical development. During 2002 we reported promising data from an early trial of APC8024, a vaccine that may have utility in treating breast, ovarian and colon cancer. APC8024 was developed from the same vaccine platform technology as Provenge, and the data we have generated in animal studies and in early human clinical trials make us very optimistic about the potential for this product candidate. Our analysis indicates that the potential market size for APC8024 in the advanced breast, ovarian, colon and lung cancer indications could be more than $3 billion. We intend to complete the APC8024 Phase I program and finalize the Phase II trial design in 2003. Dendreon's expertise in harnessing the power of the immune system provides us with significant product opportunities beyond our vaccine platform, and we capitalized on this in 2002. Our efforts to identify cancer antigens have yielded novel targets for ongoing drug development activities across a variety of therapeutic approaches. Our Trp-p8 gene platform is an example of how the identification of cancer antigens can expand our product and collaboration horizons. The Trp-p8 gene is expressed at high levels in and fexofenadine. Health-related quality of life questionnaire We used the SF-36 Health Survey, a previously validated questionnaire 17 ; . It based on a core set of generic health measures that have proved useful in determining the quality of life in different diseases and in measuring the benefits of treatments 18-24 ; . SF-36 consists of multi-item scales measuring 8 concepts physical functioning, role disability: physical, bodily pain, general health, vitality, social functioning, role disability: emotional and mental health ; . Scale scores for these domains were derived by summing up the component items within each domain. The higher scores indicated better health than the lower scores 17 ; . We excluded the items concerning bodily pain because chronic hepatitis does not cause pain. Patients completed SF-36 at baseline and immediately after finishing the antiviral treatment. The controls also completed this survey.
Not central -- role in heart disease. For example, inflammation is now considered the major factor in heart health and disease, consistent not only with clinical but also epidemiological data. Increasing numbers of people who suffer a cardiac event -- especially women and those in younger age groups -- tend to have normal cholesterol profiles, have an active lifestyle, and are generally not overweight. Yet, these people may suffer fatal episodes of cardiac events. Inflammation provides a plausible explanation for this increase. A peculiar fact long known to cardiologists and researchers alike, those suffering from heart attacks had relatively high levels of circulating C-reactive protein CRP ; . Produced in the liver, CRP is the body's response to fight inflammation. By now it is firmly established that CRP is a more reliable predictor of adverse cardiac episodes than and pseudoephedrine, for example, famotidine nizatidine.
It was as if my stomach was swelling up like a balloon when i took this medicine which i only did for 4 days before having to stop.
Merbentyl 20 Tab 20mg Kolanticon Gel S F Hyoscine Butylbrom Tab 10mg Buscopan Tab 10mg Buscopan Inj 20mg ml 1ml Amp Mebeverine HCl Oral Susp 50mg 5ml S F Mebeverine HCl Tab 135mg Mebeverine HCl Tab 100mg Mebeverine HCl Cap 200mg M R Colofac Liq 50mg 5ml S F Colofac Tab 135mg Colofac IBS Tab 135mg Colofac MR Cap 200mg Peppermint Oil Cap E C 0.2ml Peppermint Oil Cap E C 0.2ml M R Colpermin Cap E C 0.2ml M R Mintec Cap E C 0.2ml Ispag Mebeverine Gran Eff 3.5g 135mg S F Fybogel Mebeverine Eff Gran Sach S F Propantheline Brom Tab 15mg Pro-Banthine Tab 15mg Cimetidine Tab 200mg Cimetidine Tab 400mg Cimetidine Tab 800mg Cimetidine Oral Susp 200mg 5ml S F Cimetidine Tab Eff 400mg Orange ; Tagamet Tab 200mg Tagamet Tab 400mg Tagamet Tab Eff 400mg Orange ; Dyspamet Susp 200mg 5ml S F Famotieine Tab 20mg Famotidinee Tab 40mg Pepcid Tab 20mg Nizatidine Cap 150mg Nizatidine Cap 300mg Ranitidine HCl Tab 150mg and finasteride. Famotidine has a longer duration of action than either ranitidine or cimetidine. Data. Market analysis and research is used to monitor trends for products and categories and develop category management recommendations. New Product Introductions and Drug Application Approvals The Company launched several new products in fiscal 2005, most notably nicotine polacrilex gum, loratadine 10 mg tablets, miconazole 3-day combo pack and aerosol foot products comparable to the national brands Nicorette, Claritin, Monistat, Tinactin and Lotrimin, respectively. Net sales related to new products were approximately $38, 000 for fiscal 2005, $70, 000 for fiscal 2004 and $45, 000 for fiscal 2003. A product is considered new if it was added to the Company's product lines in the two most recent fiscal years that net sales are recorded. In fiscal 2005, the Company received approval from the FDA for 10 OTC drug applications. The applications were for the following products: nicotine regular gum 2mg and 4mg, nicotine mint gum 2mg and 4mg, nicotine orange gum 2mg and 4mg, famotidine 10mg tablet, loratadine oral solution 10 mg 5ml, acetaminophen extended release 650mg tablet and ibuprofen orange 200mg tablet. The Company has three OTC drug applications currently pending approval with the FDA. Competition The market for OTC pharmaceutical and nutritional products is highly competitive. Competition is based primarily on price, quality and assortment of products, customer service, marketing support and availability of new products. The Company believes it competes favorably in these areas. The Company's competition in store brand products consists of several publicly traded and privately owned companies. The competition is highly fragmented in terms of both geographic market coverage and product categories, such that a competitor generally does not compete across all product lines. Some of the Company's competitors are Alpharma Inc., Leiner Health Products Inc., LNK International Inc., NBTY Inc. and Taro Pharmaceutical Industries Ltd. The Company's store brand products also compete with nationally advertised brand name products. Most of the national brand companies have resources substantially greater than those of the Company. National brand companies could in the future manufacture store brand products or lower prices of national brand products. Additionally, competition is growing from generic prescription drug manufacturers that are switching products from Rx to OTC status. The Company competes in the nutritional area with a number of publicly traded and privately owned companies, some of which have broader product lines and larger sales volumes. PRESCRIPTION Rx ; PHARMACEUTICALS The primary activity of the Rx Pharmaceuticals segment is the development, manufacture and sale of generic prescription drug products, generally for the U.S. market. Significant Developments Agis Acquisition The Company's acquisition of Agis is a major step forward in its strategy, announced in August 2003, to grow by entering the generic prescription drug market. Management believes there are sufficient similarities and synergies between the OTC pharmaceutical and generic prescription drug businesses to allow the Company to grow by leveraging development, regulatory and manufacturing expertise, customer relationships and supply chain infrastructure. The Company believes that it may accomplish this growth by several means, including the internal development of generic drugs, acquisition and or licensing of generic drugs and acquisitions of generic drug -5 and flagyl.
By histamine can be prevented by perioperative cimetidine Adams and Morris, 1994 ; . However, such beneficial effects using other H2R antagonists i.e., famotidine and ranitidine ; , have not been observed in clinical trials Matsumoto, 1995 ; . Cimetidine treatment inhibits histamine-initiated angiogenesis via reducing vascular endothelial growth factor expression Gifford and Tirberg, 1987 ; . The activation state of intratumoral DC is a critical factor in the host response to tumors Furumoto et al., 2004 ; . Cimetidine-induced higher antigen presenting capacity of DC was observed in patients with advanced cancer compared with healthy control subjects Kubota et al., 2002 ; . IL-18, a monocyte-derived cytokine that requires cleavage with caspase-1 for activity Gu et al., 1997 ; , enhances local antitumor immune responses through activating natural killer cells and T cells Kohno et al., 1997 ; . IL-18 inhibits angiogenesis Coughlin et al., 1998 ; and induces apoptosis in tumor cells Hashimoto et al., 1999 ; . In the mouse colon cancer model, IL-18 inhibits growth of cells Tamura et al., 2003 ; , and successful prevention of colon cancer establishment is associated with elevation of serum IL-18 level Goto et al., 2002. And review the history of their development, we are constrained to conclude that they do not mean to leave room for the play and action of purely personal and arbitrary power.'" Id., quoting Yick Wo v. Hopkins, 118 U.S. 356, 369 1886 ; . Economic harm is unavoidable in all but gratuitous medical treatments. In the absence of fraud, it should be up to the buyer alone to decide how he or she wishes to spend money, just as in any other commercial context. The economic aspects of medical care should be sorted in the free market, not by a licensing board through the draconian penalty of exclusion of a credentialed physician. I. The Decision is Flawed in its Total Rejection of Dr. Sinaiko's Methodologies In its zeal to condemn Dr. Sinaiko, the MBC relies on practitioners who refuse to acknowledge possible merit in Dr. Sinaiko's treatment methodologies and in so doing, the MBC has taken sides--and very possibly the wrong side--in an ongoing medical debate. Reading such comments in the MBC's Answer as "the evidence.clearly and convincingly, leads to the factual conclusion that petitioner adheres to many of the practices espoused by Clinical Ecologists", at 11: 20-22, one cannot help but sense a bit of McCarthyism at work--a witch hunt of sorts trying to find Dr. Sinaiko guilty by association. In fact, although the Decision nowhere mentions clinical ecology or environmental medicine, the MBC devotes a substantial portion of its Answering Brief to building up the theories, only to strike them down as "unscientific in [] concept and unproven as a medical diagnosis." Answer, at pgs. 1-13. To the extent the MBC offers the discussion to provide context, the Court should know the context is incomplete. In truth, at least one court has suggested and fluconazole. By a CoMFA pharmacophore model based on QSAR analysis of potent blockers.`, for example, famotidine and omeprazole. Analysis of pteridines and creatinine in urine by hplc with serial fluorimetric and photometric detectors espinosa mansilla durn mers francisco salinas although pteridines are excreted in the urine of normal healthy persons, levels of some of these compounds seem to be modified by several diseases and galantamine. Supplemental funding from the OAR. Mellins and her team have pursued issues of medical adherence for women and, with pilot funding from the Columbia-Rockefeller Center for AIDS Research CR-CFAR ; , for children. Remien and Ezer Kang are currently funded through another CR-CFAR pilot grant to expand this work to Asian-American and Pacific Islanders. Robert Klitzman has addressed disclosure of serostatus and stigma towards HIV-positive persons, particularly HIV-positive health care providers. He has extended this work to physicians who have a serious illness such as HIV, exploring the impact of their health on communication with and clinical care of their patients. This work has led to a newly funded study on privacy and disclosure of genetic diseases Klitzman; NHGRI ; . The biomedical and clinical research initiatives affiliated with the HIV Center are exemplified by a productive collaboration funded through the Columbia-Rockefeller Center for AIDS Research CR-CFAR ; . Ehrhardt is a Co-Director of the CFAR's Clinical Core with Scott Hammer and Martin Markowitz ; . HIV Center behavioral and social scientists e.g., Mellins, Joyce Hunter, Remien, and Carballo-Diguez ; collaborate with clinical and basic science researchers in community outreach and recruitment, pilot studies, and clinical trials. Carballo-Diguez is collaborating with Wafaa El-Sadr, on microbicide research within the HIV Prevention Trials Network. Karen Marder, Steven Albert, Judith Rabkin, and Wilfred Van Gorp are studying the neurological and psychiatric sequelae of HIV disease and clinical treatment strategies, for example, long term use of famotidine. Abstract: The aim of this study was to evaluate the effects of H antazoline and astemizole ; or H cimetidine and famotid8ne ; histamine receptor antagonists on the clonic phase, tonic seizures and morality of mice challenged with aminophylline to induce convulsions in mice. Moreover, the total plasma and brain concentrations of theophylline were evaluated. Astemizole 1 mg kg ; did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg kg, it significantly reduced the CD# value of aminophylline from 249 mg kg to 211 mg kg p 0.01 ; . The remaining histamine receptor antagonists studied i.e., antazoline up to 1 mg kg ; , cimetidine up to 40 mg kg ; and camotidine up to 10 mg kg ; had no impact on seizure susceptibility in aminophylline-induced convulsions. Furthermore, astemizole 2 mg kg ; decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 4.5 to 32.1 4.3 min p 0.01 ; . It is noteworthy that astemizole, a novel H receptor antagonist, did not alter the brain and plasma levels of theophylline, so the existence of pharmacokinetic interactions was excluded. Our results indicate that some interactions between methylxanthines and histamine receptor antagonists may be clinically important since these drugs are usually combined during the treatment of status asthmaticus. Key words: astemizole, antazoline, cimetidine, famotidine, aminophylline-induced convulsions, mortality and glibenclamide.
Sized in diagnosis and treatment, as well as an evolution in the roles of patients and clinicians, have ushered in a new cognitive era in patient care. Providers are being asked to help patients translate and contextualize medical information, as well as to improve treatment adherence by involving patients in their care. At the same time, clinicians are increasingly being required to measure and report on various aspects of care processes and outcomes. These variables are driving the need for increased support from information technologies. Such changes necessitate new measurement and management tools in addition to new approaches to partnering with patients and systematically managing conditions. much as medical providers require new types of surgical and diagnostic tools as medical technology advances, so too will they need Internet and informatics. In either scenario, women will benefit the most from the drug that works best for them and glucovance. Famotidine without prescription available. Famotidine is an h histamine ; blocker and inderal and famotidine.

Famotidine pregnancy Talk to your prescriber or health care professional about other medicines that may increase the effect of famotidind before taking any prescription or over-the-counter medicines. Famotidine oral Antibiotic medications are low cost, this graph is likely to be indicative of the overall trends in utilisation of antibiotic medications Figures 21 and 22 ; . There is a difference between the two data sets comparing antibiotic medications dispensed although the trends in each case are similar. This is an example where antibiotic strategies would potentially be more useful if based on Primenet data Figure 23 ; . There appear to be no material differences between the two data sets comparing the periods of supply per prescription dispensed Figure 24 and itraconazole. Home articles health topics diseases & conditions tests & procedures drugs & supplements symptoms site map quick links gerd gerd diet gerd symptoms nexium prilosec protonix prevacid aciphex zantac famotidine cimetidine pepcid precautions and warnings with famotidine some precautions and warnings with famotidine to be aware of include potential drug interactions, the safety of taking famotidine if you have poor kidney function, and people who should not take this medicine at all such as those who are allergic to famotidine or its inactive components. Cost of Famotidine

Discount Famotidine AUC, Cmax and Cmin of efavirenz decreased by 36%, 21%, and 47%, respectively. The steady-state AUC, Cmax and Cmin of the active carbamazepine epoxide metabolite remained unchanged. Carbamazepine plasma levels should be monitored periodically. There are no data with coadministration of higher doses of either medicinal product; therefore, no dose recommendation can be made, and alternative anticonvulsant treatment should be considered. Other anticonvulsants: no data are available on the potential interactions of efavirenz with phenytoin, phenobarbital, or other anticonvulsants that are substrates of CYP450 isozymes. When efavirenz is administered concomitantly with these agents, there is a potential for reduction or increase in the plasma concentrations of each agent; therefore, periodic monitoring of plasma levels should be conducted. Specific interaction studies have not been performed with efavirenz and vigabatrin or gabapentin. Clinically significant interactions would not be expected since vigabatrin and gabapentin are exclusively eliminated unchanged in the urine and would be unlikely to compete for the same metabolic enzymes and elimination pathways as efavirenz. Lipid-lowering agents: Co-administration of efavirenz with the HMG-CoA reductase inhibitors atorvastatin, pravastatin, or simvastatin has been shown to reduce the plasma concentration of the statin in uninfected volunteers. Cholesterol levels should be periodically monitored. Dosage adjustments of statins may be required refer to the Summary of Product Characteristics for the statin ; . Atorvastatin: co-administration of efavirenz 600 mg orally once daily ; with atorvastatin 10 mg orally once daily ; in uninfected volunteers decreased the steady-state AUC and Cmax of atorvastatin by 43% and 12%, respectively, of 2-hydroxy atorvastatin by 35% and 13%, respectively, of 4-hydroxy atorvastatin by 4% and 47%, respectively, and of total active HMG-CoA reductase inhibitors by 34% and 20%, respectively, compared to atorvastatin administered alone. Pravastatin: co-administration of efavirenz 600 mg orally once daily ; with pravastatin 40 mg orally once daily ; in uninfected volunteers decreased the steady-state AUC and Cmax of pravastatin by 40% and 18%, respectively, compared to pravastatin administered alone. Simvastatin: co-administration of efavirenz 600 mg orally once daily ; with simvastatin 40 mg orally once daily ; in uninfected volunteers decreased the steady-state AUC and Cmax of simvastatin by 69% and 76%, respectively, of simvastatin acid by 58% and 51%, respectively, of total active HMG-CoA reductase inhibitors by 60% and 62%, respectively, and of total HMG-CoA reductase inhibitors by 60% and 70%, respectively, compared to simvastatin administered alone. Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values. No dosage adjustment is necessary for efavirenz. Other interactions: Antacids famotidine: neither aluminium magnesium hydroxide antacids nor famotidine altered the absorption of efavirenz in uninfected volunteers. These data suggest that alteration of gastric pH by other medicinal products would not be expected to affect efavirenz absorption. Oral contraceptives: only the ethinyloestradiol component of oral contraceptives has been studied. The AUC following a single dose of ethinyloestradiol was increased 37% ; after multiple dosing of efavirenz. No significant changes were observed in Cmax of ethinyloestradiol. The clinical significance of these effects is not known. No effect of a single dose of ethinyloestradiol on efavirenz Cmax or AUC was observed. Because the potential interaction of efavirenz with oral contraceptives has not been fully characterised, a reliable method of barrier contraception must be used in addition to oral contraceptives. Methadone: in a study of HIV infected IV drug users, co-administration of efavirenz with methadone resulted in decreased plasma levels of methadone and signs of opiate withdrawal. The methadone dose. Mebeverine HCl Oral Susp 50mg 5ml S F Mebeverine HCl Tab 135mg Mebeverine HCl Tab 100mg Mebeverine HCl Cap 200mg M R Colofac Liq 50mg 5ml S F Colofac Tab 135mg Colofac MR Cap 200mg Peppermint Oil Cap E C 0.2ml Peppermint Oil Cap E C 0.2ml M R Colpermin Cap E C 0.2ml M R Mintec Cap E C 0.2ml Ispag Mebeverine Gran Eff 3.5g 135mg S F Fybogel Mebeverine Eff Gran Sach S F Propantheline Brom Tab 15mg Pro-Banthine Tab 15mg Cimetidine Tab 200mg Cimetidine Tab 400mg Cimetidine Tab 800mg Cimetidine Oral Soln 200mg 5ml Cimetidine Oral Susp 200mg 5ml S F Cimetidine Tab Eff 400mg Orange ; Tagamet Tab 200mg Tagamet Tab 400mg Tagamet Syr 200mg 5ml Tagamet Tab Eff 400mg Orange ; Camotidine Tab 20mg Famotidime Tab 40mg Pepcid Tab 20mg Pepcid Tab 40mg Nizatidine Cap 150mg Nizatidine Cap 300mg Axid Cap 150mg Axid Cap 300mg Zinga 150 Cap 150mg Ranitidine HCl Tab 150mg Ranitidine HCl Tab 300mg. Drug H1-receptor antagonists Nonsedating * Fexofenadine Allegra ; Desloratadine Clarinex ; Loratadine Claritin ; Cetirizine Zyrtec ; Sedating Hydroxyzine Atarax ; Diphenhydramine Benadryl ; Cyproheptadine Periactin ; H2-receptor antagonists Cimetidine Tagamet ; Ranitidine Zantac ; Famotidlne Pepcid ; H1- and H2- receptor antagonist Doxepin Sinequan ; Corticosteroids Prednisone Methylprednisolone Medrol ; Leukotriene antagonists Zafirlukast Accolate ; Montelukast Singulair ; Epinephrine Ana-Guard 1: 000 ; EpiPen 1: 000 ; EpiPen Jr 1: 2, 000 ; Immunotherapy Cyclosporin Methotrexate 2-3 mg kg daily 2.5 mg PO bid for 3 days of the week 4-6 mg kg daily 5 mg PO bid for 3 days of the week 100 mg ml 25 mg ml 25 mg, 50 mg, 100 mg 2.5 mg 20 mg bid 10 mg qd Injection 0.3 mL dose SC 0.3 mg dose Children 12 yr: 0.15 mg dose 20 mg qod with gradual taper 16 mg qod with gradual tapering Many other dose schedules Many other dose schedules - - 5 mg 5 ml -- 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg 2 mg, 4 mg, 8 mg, 16 mg, 24 mg, 32 mg 10 mg qid 50 mg qid 10 mg ml 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg 400 mg bid 150 mg bid 20 mg bid 800 mg bid 300 mg bid 40 mg bid 300 mg 5cc 75 mg 5cc 40 mg 5cc 200mg, 300mg, mg, 800 mg 150 mg, 300 mg 20 mg, 40 mg 10 mg qid 25 mg bid 4 mg qid 50 mg qid 50 mg qid 8 mg qid 10 mg 5 ml Susp. 25 mg 5ml Elixir 12.5 mg 5ml Syrup 6.25 mg 5 ml 2 mg 5ml 10mg, 25 mg, 50 mg, 100 mg 25, 50 mg 12.5 Chew Tab 8 mg 180 mg qd 5 mg 10 mg qd 10 mg qd 180 mg bid 10 mg 20 mg bid 10 mg bid.

Dant; and 4 ; famotidine Pepcid ; . Controlled trials of these 4 treatments have been negative, inconclusive, or so methodologically flawed as to preclude meaningful conclusions.810 Still other somatic treatments, including antiyeast diets, have not been subjected to controlled trials.9 Several of these popular treatments are not free of adverse side effects; for example, vitamin B6 toxicity has been linked to peptic ulcer disease.11 Psychosocial SQTs for autism include facilitated communication FC ; and sensory-motor integration SMI ; . FC is premised on the notion that autistic children suffer not from an intellectual and affective impairment but from an exclusively motor impairment termed developmental apraxia, which impedes their ability to speak properly.12 Hence, with the aid of a facilitator who guides their hand movements, these children can ostensibly type out complete sentences on a computer keyboard or letter pad. Nevertheless, controlled studies demonstrate overwhelmingly that FC is ineffective and that the resultant communications are a product of inadvertent facilitator control over the child's hand movements.13, 14 Although this "ideomotor effect" has been well documented by researchers for decades, the proponents of FC never considered it as an alternative explanation for FC's seemingly remarkable effects.15 In addition to gratuitously raising the hopes of the parents of autistic children, FC has resulted in numerous uncorroborated allegations of sexual and physical abuse against these parents.16 SMI is premised on the notion that autism is attributable to dysfunctions in brain areas responsible for sensory eg, visual, tactile, vestibular, and kinesthetic ; input and motor output. Common SMI treatments include spinning children in chairs, engaging them in balance activities, and brushing their body parts.17 Although widely used, SMI treatments have not been shown to be efficacious in carefully controlled studies.18 Efficacious pharmacologic treatments for autism include dopamine antagonists such as haloperidol Haldol ; , atypical antipsychotics such as risperidone Risperdal ; , and selective serotonin reuptake inhibitors such as fluoxetine Prozac ; . Although these medications do not cure the core features of autism, they seem useful in curtailing certain problematic behaviors including temper outbursts, hyperactivity, and repetitive actions.19 The most efficacious psychosocial treatment for autism is applied behavior analysis, which focuses on positively reinforcing and shaping selected target behaviors such as appropriate interpersonal interactions and use of correct language. In controlled within-subject studies, applied behavior analysis has demonstrated positive effects on autistic children's social and intellectual behaviors, although almost all of these children are left with serious deficits in adaptive functioning.8, 9 and fexofenadine. Colofac Tab 135mg Colofac MR Cap 200mg Peppermint Oil Cap E C 0.2ml Peppermint Oil Cap E C 0.2ml M R Colpermin Cap E C 0.2ml M R Mintec Cap E C 0.2ml Ispag Mebeverine Gran Eff 3.5g 135mg S F Fybogel Mebeverine Eff Gran Sach S F Propantheline Brom Tab 15mg Pro-Banthine Tab 15mg Cimetidine Tab 200mg Cimetidine Tab 400mg Cimetidine Tab 800mg Cimetidine Oral Soln 200mg 5ml Cimetidine Oral Soln 200mg 5ml S F Tagamet Tab 400mg Peptimax 400 Tab 400mg Famotidine Tab 20mg Famotidine Tab 40mg Nizatidine Cap 150mg Nizatidine Cap 300mg Ranitidine HCl Tab 150mg Ranitidine HCl Tab 300mg Ranitidine HCl Oral Soln 75mg 5ml S F Ranitidine HCl Tab Eff 150mg Ranitidine HCl Tab Eff 300mg Ranitidine HCl Tab 75mg Zantac Tab 150mg Zantac Disper Tab 150mg Zantac Tab 300mg Zantac Syr 150mg 10ml S F Gavilast Tab 75mg Gppe Pack HeliClear Gppe Pack HeliMet HeliClear Triple Pack HeliMet Triple Pack. Ingredient 1. Estradiol 2. Famotidine 3. Metoprolol.